Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016 (2016), Article ID 2405176, 9 pages
http://dx.doi.org/10.1155/2016/2405176
Research Article

A Feed-Forward Circuit of Endogenous PGC-1α and Estrogen Related Receptor α Regulates the Neuronal Electron Transport Chain

1Neurogenomics Lab and Harvard Parkinson Personalized Medicine Initiative, Harvard Medical School and Brigham and Women’s Hospital, Cambridge, MA 02139, USA
2Department of Neurology, Brigham and Women’s Hospital, Boston, MA 02115, USA
3Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
4Biomarkers Program, Harvard NeuroDiscovery Center, Boston, MA 02115, USA

Received 3 November 2015; Accepted 3 February 2016

Academic Editor: Rosa A. González-Polo

Copyright © 2016 Rachit Bakshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Austin and J. St-Pierre, “PGC1α and mitochondrial metabolism—emerging concepts and relevance in ageing and neurodegenerative disorders,” Journal of Cell Science, vol. 125, no. 21, pp. 4963–4971, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. V. K. Mootha, C. M. Lindgren, K.-F. Eriksson et al., “PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes,” Nature Genetics, vol. 34, no. 3, pp. 267–273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Handschin and B. M. Spiegelman, “Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism,” Endocrine Reviews, vol. 27, no. 7, pp. 728–735, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Wenz, S. G. Rossi, R. L. Rotundo, B. M. Spiegelman, and C. T. Moraes, “Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20405–20410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Finkel, “Cell biology: a clean energy programme,” Nature, vol. 444, no. 7116, pp. 151–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Austin, E. Klimcakova, and J. St-Pierre, “Impact of PGC-1α on the topology and rate of superoxide production by the mitochondrial electron transport chain,” Free Radical Biology and Medicine, vol. 51, no. 12, pp. 2243–2248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. E. Raichle and D. A. Gusnard, “Appraising the brain's energy budget,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10237–10239, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. V. K. Mootha, C. Handschin, D. Arlow et al., “Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6570–6575, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Arany, H. He, J. Lin et al., “Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle,” Cell Metabolism, vol. 1, no. 4, pp. 259–271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. L. M. Rohas, J. St-Pierre, M. Uldry, S. Jäger, C. Handschin, and B. M. Spiegelman, “A fundamental system of cellular energy homeostasis regulated by PGC-1α,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 19, pp. 7933–7938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Lin, C. Handschin, and B. M. Spiegelman, “Metabolic control through the PGC-1 family of transcription coactivators,” Cell Metabolism, vol. 1, no. 6, pp. 361–370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. Lehman, P. M. Barger, A. Kovacs, J. E. Saffitz, D. M. Medeiros, and D. P. Kelly, “Peroxisome proliferator-activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis,” Journal of Clinical Investigation, vol. 106, no. 7, pp. 847–856, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. S. N. Schreiber, D. Knutti, K. Brogli, T. Uhlmann, and A. Kralli, “The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor α (ERRα),” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 9013–9018, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Zheng, Z. Liao, J. J. Locascio et al., “PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease,” Science Translational Medicine, vol. 2, no. 52, Article ID 52ra73, 2010. View at Publisher · View at Google Scholar
  15. L. Cui, H. Jeong, F. Borovecki, C. N. Parkhurst, N. Tanese, and D. Krainc, “Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration,” Cell, vol. 127, no. 1, pp. 59–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Weydt, V. V. Pineda, A. E. Torrence et al., “Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration,” Cell Metabolism, vol. 4, no. 5, pp. 349–362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Thau, S. Knippenberg, S. Körner, K. J. Rath, R. Dengler, and S. Petri, “Decreased mRNA expression of PGC-1α and PGC-1α-regulated factors in the SOD1G93A ALS mouse model and in human sporadic ALS,” Journal of Neuropathology and Experimental Neurology, vol. 71, no. 12, pp. 1064–1074, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Mudò, J. Mäkelä, V. Di Liberto et al., “Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease,” Cellular and Molecular Life Sciences, vol. 69, no. 7, pp. 1153–1165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-H. Shin, H. S. Ko, H. Kang et al., “PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease,” Cell, vol. 144, no. 5, pp. 689–702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. J. St-Pierre, S. Drori, M. Uldry et al., “Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators,” Cell, vol. 127, no. 2, pp. 397–408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Lin, P.-H. Wu, P. T. Tarr et al., “Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice,” Cell, vol. 119, no. 1, pp. 121–135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Valle, A. Álvarez-Barrientos, E. Arza, S. Lamas, and M. Monsalve, “PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells,” Cardiovascular Research, vol. 66, no. 3, pp. 562–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Giguere, N. Yang, P. Segui, and R. M. Evans, “Identification of a new class of steroid hormone receptors,” Nature, vol. 331, no. 6151, pp. 91–94, 1988. View at Publisher · View at Google Scholar · View at Scopus
  24. H. S. Ranhotra, “Estrogen-related receptor alpha and mitochondria: tale of the titans,” Journal of Receptor and Signal Transduction Research, vol. 35, no. 5, pp. 386–390, 2015. View at Publisher · View at Google Scholar
  25. S. D. Johnston, X. Liu, F. Zuo et al., “Estrogen-related receptor alpha 1 functionally binds as a monomer to extended half-site sequences including ones contained within estrogen-response elements,” Molecular Endocrinology, vol. 11, no. 3, pp. 342–352, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-M. Vanacker, E. Bonnelye, S. Chopin-Delannoy, C. Delmarre, V. Cavaillès, and V. Laudet, “Transcriptional activities of the orphan nuclear receptor ERR α (estrogen receptor-related receptor-α),” Molecular Endocrinology, vol. 13, no. 5, pp. 764–773, 1999. View at Google Scholar · View at Scopus
  27. G. Deblois, J. A. Hall, M.-C. Perry et al., “Genome-wide identification of direct target genes implicates estrogen-related receptor α as a determinant of breast cancer heterogeneity,” Cancer Research, vol. 69, no. 15, pp. 6149–6157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. U. Smith, “Pioglitazone: mechanism of action,” International Journal of Clinical Practice, no. 121, pp. 13–18, 2001. View at Google Scholar
  29. I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith, “Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo,” Diabetes, vol. 54, no. 5, pp. 1392–1399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. R. Carta and T. Simuni, “Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease,” Expert Opinion on Investigational Drugs, vol. 24, no. 2, pp. 219–227, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation,” Journal of Neurochemistry, vol. 88, no. 2, pp. 494–501, 2004. View at Google Scholar · View at Scopus
  32. N. Schintu, L. Frau, M. Ibba et al., “PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease,” European Journal of Neuroscience, vol. 29, no. 5, pp. 954–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. R. L. Hunter, N. Dragicevic, K. Seifert et al., “Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system,” Journal of Neurochemistry, vol. 100, no. 5, pp. 1375–1386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. G. K. Ulusoy, T. Celik, H. Kayir, M. Gürsoy, A. T. Isik, and T. I. Uzbay, “Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease,” Brain Research Bulletin, vol. 85, no. 6, pp. 380–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1,” Cell, vol. 98, no. 1, pp. 115–124, 1999. View at Publisher · View at Google Scholar
  36. D. W. Dickson, H. Fujishiro, A. DelleDonne et al., “Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease,” Acta Neuropathologica, vol. 115, no. 4, pp. 437–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Elstner, C. M. Morris, K. Heim et al., “Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death,” Acta Neuropathologica, vol. 122, no. 1, pp. 75–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. D. Ryan, N. Dolatabadi, S. F. Chan et al., “Erratum: isogenic human iPSC parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription,” Cell, vol. 155, no. 7, pp. 1652–1653, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Da Cruz, P. A. Parone, V. S. Lopes et al., “Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS,” Cell Metabolism, vol. 15, no. 5, pp. 778–786, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Ciron, S. Lengacher, J. Dusonchet, P. Aebischer, and B. L. Schneider, “Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function,” Human Molecular Genetics, vol. 21, no. 8, pp. 1861–1876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Clark, J. M. Silvaggi, T. Kiselak et al., “Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf,” PLoS ONE, vol. 7, no. 11, Article ID e48925, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, “Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial,” The Lancet Neurology, vol. 14, no. 4, pp. 795–803, 2015. View at Publisher · View at Google Scholar
  43. R. Brauer, K. Bhaskaran, N. Chaturvedi, D. T. Dexter, L. Smeeth, and I. Douglas, “Glitazone treatment and incidence of Parkinson’s disease among people with diabetes: a retrospective Cohort study,” PLoS Medicine, vol. 12, no. 7, Article ID e1001854, 2015. View at Publisher · View at Google Scholar
  44. J. Kallen, J.-M. Schlaeppi, F. Bitsch et al., “Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor α (ERRα): crystal structure of ERRα ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1α,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 49330–49337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Suetsugi, L. Su, K. Karlsberg, Y.-C. Yuan, and S. Chen, “Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors,” Molecular Cancer Research, vol. 1, no. 13, pp. 981–991, 2003. View at Google Scholar · View at Scopus
  46. C. Handschin and V. K. Mootha, “Estrogen-related receptor α (ERRα): a novel target in type 2 diabetes,” Drug Discovery Today: Therapeutic Strategies, vol. 2, no. 2, pp. 151–156, 2005. View at Publisher · View at Google Scholar · View at Scopus